Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott Laboratories

US Baby Formula Crisis Could See Some Relief As FDA, Abbott Agree On Deal

The baby formula shortage that has morphed into a crisis in the U.S. could soon see some relief following an agreement between market leader Abbott Laboratories (NYSE: ABT) and the Food and Drug Administration.

Benzinga

Abbott Spent $5B On Stock Buybacks Instead Of Fixing Its Baby Formula Factory

The fear of not knowing where your child’s next meal comes from is something that no parent should face. But, because of a recall of Abbott Laboratories’ (NYSE: ABT) Similac and other popular baby formula brands, stores throughout the nation are limiting how much formula parents can buy.

Benzinga

Baby-formula shortage spurs US to prod Abbott over access

WASHINGTON — The Biden administration on Friday urged Abbott Laboratories to do more to ensure low-income families on federal assistance have access to baby formula, amid a nationwide shortage.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Baby formula shortage fueling spike in milk bank interest

The U.S. baby formula shortage has sparked a surge of interest among moms who want to donate breast milk to help bridge the supply gap as well as those seeking to keep their babies fed

The Independent UK

After baby formula recall, Abbott says it can restart production at Michigan site within 2 weeks of FDA approval

Abbott Laboratories said it could have some of its recalled infant formulas back on store shelves within eight to 10 weeks after the U.S. Food and Drug Administration gives its approval, though it’s unclear when that approval may come.

Chicago Tribune

Tainted baby-formula risk was seen months before Abbott’s recall

Federal inspectors spotted the potential for baby formula made at an Abbott Laboratories plant to become contaminated months before a recall that exacerbated a nationwide shortage, a government document shows.

Tribune News Service

Amid Baby Formula Shortage, Retailers Put Cap On Purchases: Report

The U.S. faced a nationwide shortage of the most popular baby formula brands in the week starting April 24, according to the latest figures from Datasembly, which tracks out-of-stock messages on retailers' websites and apps. An average rate is less than 10%. Reasons For The Shortage: Supply chain issues caused by the COVID-19…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Large-Cap Stocks Rated 'Strong Buy' to Snatch-Up in May

Since the persistent Ukraine-Russia war, rising inflationary pressures, and Fed's upcoming interest rate hikes are expected to keep the stock market volatile in the near term, investors seek opportunities to invest in large-cap stocks, which hold the potential to generate relatively stable returns. So, we think it could be wise…

StockNews.com

Here's How Much $100 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.78% on an annualized basis producing an average annual return of 20.13%. Currently, Abbott Laboratories has a market capitalization of $196.98 billion.

Benzinga

Peering Into Abbott Laboratories's Recent Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 9.21% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.69% of all regular shares that are available for trading.

Benzinga

Expert Ratings for Abbott Laboratories

Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter:

Benzinga

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Benzinga

Abbott Laboratories: Q1 Earnings Insights

Abbott Laboratories (NYSE:ABT) reported its Q1 earnings results on Wednesday, April 20, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

If You Invested $1000 In Abbott Laboratories 5 Years Ago, Here's How Much You Would Have Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.67% on an annualized basis producing an average annual return of 21.94%. Currently, Abbott Laboratories has a market capitalization of $209.78 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Earnings Preview: Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2022-04-20. Here's what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will report an earnings per share (EPS) of $1.47.

StockNews.com

Abbott Laboratories vs. Zimmer Biomet Holdings: Which Medical Device Stock is a Better Buy?

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

Benzinga

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga

Looking Into Abbott Laboratories's Recent Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 28.81% since its last report. The company recently reported that it has 13.33 million shares sold short, which is 0.76% of all regular shares that are available for trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eton Pharmaceuticals Names James Gruber Finance Chief

Eton Pharmaceuticals Inc (NASDAQ:ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through May to ensure a smooth transition. Mr. Gruber, most recently, was the U.S. Controller at Horizon Therapeutics (NASDAQ:HZNP) for seven years, where he oversaw…

StockNews.com

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

Salon

DeJoy may have new conflict of interest

Justice Department urged to investigate after watchdog group found DeJoy owns stock in Abbott Laboratories

Benzinga

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 15.1%. Currently, Abbott Laboratories has a market capitalization of $211.63 billion.

Benzinga

Abbott Laboratories Whale Trades For March 29

A whale with a lot of money to spend has taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 11 strange trades.

Benzinga

FDA Inspection Flags Quality Control Issues At Abbott's Michigan Facility

An inspection at the Abbott Laboratories (NYSE: ABT) facility in Sturgis, Michigan,

Benzinga

Analyzing Abbott Laboratories's Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 15.69% since its last report. The company recently reported that it has 10.37 million shares sold short, which is 0.59% of all regular shares that are available for trading.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.